Top

30-04-2024 | Pathology | REVIEW

Antibody-Mediated Rejection: Mechanisms, Pathology, and Therapeutics

Authors: Shourjo Chakravorty, Shambhu Aryal, Adam Cochrane, Steven D. Nathan

Published in: Current Pulmonology Reports

Abstract

Purpose of Review

The goal of this paper is to review the latest advances in antibody-mediated rejection with regards to lung transplantation. We review definitions, mechanisms, pathology, and the most recent therapeutics that have been trialed for treating AMR. We hope to answer questions regarding diagnostic ambiguity that previously surrounded AMR and hope to shed light to the latest treatments which have shown promise in recent clinical trials.

Recent Findings

We review the benefits of single bead Luminex assays, and how the implementation of these assays has improved detection for donor specific antibodies, a key component in the diagnosis of AMR. We also explore other serum markers that may be beneficial in the diagnosis of AMR such as p-S5RP, and cell- free DNA.

Summary

There are new treatment options to consider such as the IL6 inhibitors Tocilizumab and clazakizumab, as well as tyrosine kinase inhibitors such as felzartamab or inflimidase, all of which have shown some promise for treating AMR.

Chambers DC, Cherikh WS, Goldfarb SB, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-fifth adult lung and heart-lung transplant report-2018; Focus theme: Multiorgan Transplantation. J Heart Lung Transplant. 2018;37:1169–83. https://doi.org/10.1016/j.healun.2018.07.020.CrossRefPubMed

Todd JL, Neely ML, Kopetskie H, et al. Risk factors for acute rejection in the first year after lung transplant. A multicenter study. Am J Respir Crit Care Med. 2020;202(4):576–85.PubMedPubMedCentralCrossRef

Trulock EP, Christie JD, Edwards LB, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult lung and heart-lung transplantation report-2007. J Heart Lung Transplant. 2007;26(8):782–95.PubMedCrossRef

Calabrese F, Roden AC, Pavlisko E, Lunardi F, Neil D, Adam B, Hwang D, Goddard M, Berry GJ, Ivanovic M, Thüsen JV, Gibault L, Lin CY, Wassilew K, Glass C, Westall G, Zeevi A, Levine DJ, Roux A. Lung allograft standardized histological analysis (LASHA) template: a research consensus proposal. J Heart Lung Transplant. 2022;41(10):1487–500. https://doi.org/10.1016/j.healun.2022.06.021. Epub 2022 Jul 3.CrossRefPubMed

Burton CM, Iversen M, Carlsen J, et al. Acute cellular rejection is a risk factor for bronchiolitis obliterans syndrome independent of post-transplant baseline FEV1. J Heart Lung Transplant. 2009;28(9):888–93.PubMedCrossRef

Girnita AL, McCurry KR, Iacono AT, et al. HLA-specific antibodies are associated with high-grade and persistent-recurrent lung allograft acute rejection. J Heart Lung Transplant. 2004;23:1135–41.PubMedCrossRef

Avtaar Singh SS, De Das S, Al-Adhami A, Singh R, Hopkins PM, Curry PA. Primary graft dysfunction following lung transplantation: from pathogenesis to future frontiers. World J Transplant. 2023;13(3):58–85. https://doi.org/10.5500/wjt.v13.i3.58.CrossRefPubMedPubMedCentral

Garces JC, Giusti S, Staffeld-Coit C, Bohorquez H, Cohen AJ, Loss GE. Antibody-Mediated Rejection: A Review. Ochsner J. 2017;17(1):46–55.PubMedPubMedCentral

•• Bery AI, Hachem RR. Antibody-mediated rejection after lung transplantation. Ann Transl Med. 2020;8(6):411. https://doi.org/10.21037/atm.2019.11.86. This paper gives a very good overview of AMR and discusses some of the latest developments with regards to diagnosing AMR and discusses some of the latest therapeutics that are promising for treating AMR.CrossRefPubMedPubMedCentral

10.

Frost AE, Jammal CT, Cagle PT. Hyperacute rejection following lung transplantation. Chest. 1996;110:559–62.PubMedCrossRef

11.

Kulkarni HS, Bemiss BC, Hachem RR. Antibody-mediated rejection in lung transplantation. Curr Transplant Rep. 2015;2:316–23.PubMedPubMedCentralCrossRef

12.

Badesch DB, Zamora M, Fullerton D, et al. Pulmonary capillaritis: a possible histologic form of acute pulmonary allograft rejection. J Heart Lung Transplant. 1998;17:415–22.PubMed

13.

Magro CM, Deng A, Pope-Harman A, et al. Humorally mediated posttransplantation septal capillary injury syndrome as a common form of pulmonary allograft rejection: a hypothesis. Transplantation. 2002;74:1273–80.PubMedCrossRef

14.

Otani S, Davis AK, Cantwell L, et al. Evolving experience of treating antibody-mediated rejection following lung transplantation. Transpl Immunol. 2014;31:75–80.PubMedCrossRef

15.

Witt CA, Gaut JP, Yusen RD, et al. Acute antibody-mediated rejection after lung transplantation. J Heart Lung Transplant. 2013;32:1034–40. https://doi.org/10.1016/j.healun.2013.07.004.CrossRefPubMed

16.

Thomas KA, Valenzuela NM, Reed EF. The perfect storm: HLA antibodies, complement, FcγRs, and endothelium in transplant rejection. Trends Mol Med. 2015;21(5):319–29.PubMedPubMedCentralCrossRef

17.

Murata K, Baldwin WM 3rd. Mechanisms of complement activation, C4d deposition, and their contribution to the pathogenesis of antibody-mediated rejection. Transplant Rev (Orlando). 2009;23(3):139–50.PubMedCrossRef

18.

Bos S, Milross L, Filby AJ, Vos R, Fisher AJ. Immune processes in the pathogenesis of chronic lung allograft dysfunction: identifying the missing pieces of the puzzle. Eur Respir Rev. 2022;31(165):220060.PubMedPubMedCentralCrossRef

19.

Nunoda S. Impact of pretransplant antibodies on outcomes after heart transplantation. Curr Opin Organ Transplant. 2019;24(3):220–6.PubMedPubMedCentralCrossRef

20.

Roux A, Le Lan IB, Holifanjaniaina S, et al. Antibody-mediated rejection in lung transplantation: clinical outcomes and donor-specific antibody characteristics. Am J Transplant. 2016;16:1216–28.PubMedCrossRef

21.

Angaswamy N, Tiriveedhi V, Sarma NJ, et al. Interplay between immune responses to HLA and non-HLA self-antigens in allograft rejection. Hum Immunol. 2013;74:1478–85.PubMedCrossRef

22.

Tikkanen JM, Singer LG, Kim SJ, Li Y, Binnie M, Chaparro C, Chow CW, Martinu T, Azad S, Keshavjee S, Tinckam K. De Novo DQ Donor-specific antibodies are associated with chronic lung allograft dysfunction after lung transplantation. Am J Respir Crit Care Med. 2016;194(5):596–606.PubMedCrossRef

23.

Snyder LD, Wang Z, Chen DF, Reinsmoen NL, Finlen-Copeland CA, Davis WA, Zaas DW, Palmer SM. Implications for human leukocyte antigen antibodies after lung transplantation: a 10-year experience in 441 patients. Chest. 2013;144(1):226–33.PubMedPubMedCentralCrossRef

24.

Morrell MR, Pilewski JM, Gries CJ, Pipeling MR, Crespo MM, Ensor CR, Yousem SA, D’Cunha J, Shigemura N, Bermudez CA, McDyer JF, Zeevi A. De novo donor-specific HLA antibodies are associated with early and high-grade bronchiolitis obliterans syndrome and death after lung transplantation. J Heart Lung Transplant. 2014;33(12):1288–94.PubMedCrossRef

25.

Smith JD, Banner NR, Hamour IM, Ozawa M, Goh A, Robinson D, Terasaki PI, Rose ML. De novo donor HLA-specific antibodies after heart transplantation are an independent predictor of poor patient survival. Am J Transplant. 2011;11(2):312–9.PubMedCrossRef

26.

Jackson JA, Kim EJ, Begley B, Cheeseman J, Harden T, Perez SD, Thomas S, Warshaw B, Kirk AD. Urinary chemokines CXCL9 and CXCL10 are noninvasive markers of renal allograft rejection and BK viral infection. Am J Transplant. 2011;11(10):2228–34.PubMedPubMedCentralCrossRef

27.

Hartono C, Muthukumar T, Suthanthiran M. Noninvasive diagnosis of acute rejection of renal allografts. Curr Opin Organ Transplant. 2010;15(1):35–41.PubMedPubMedCentralCrossRef

28.

Wood-Trageser MA, Lesniak AJ, Demetris AJ. Enhancing the value of histopathological assessment of allograft biopsy monitoring. Transplantation. 2019;103(7):1306–22.PubMedPubMedCentralCrossRef

29.

Süsal C, Opelz G, Morath C. Role and Value of Luminex(^®)-Detected HLA Antibodies before and after Kidney Transplantation. Transfus Med Hemother. 2013;40(3):190–5. https://doi.org/10.1159/000351314. Epub 2013 May 6.CrossRefPubMedPubMedCentral

30.

Maguire O, Tario JD Jr, Shanahan TC, Wallace PK, Minderman H. Flow cytometry and solid organ transplantation: a perfect match. Immunol Invest. 2014;43(8):756–74.PubMedPubMedCentralCrossRef

31.

Scornik J. Detection of alloantibodies by flow cytometry: relevance to clinical transplantation. Cytometry. 1995;22:259–63.PubMedCrossRef

32.

Tait B, Hudson F, Cantwell L, et al. Review article: Luminex technology for HLA antibody detection in organ transplantation. Nephrol. 2009;14:247–54.PubMedCrossRef

33.

Lunardi F, Vedovelli L, Pezzuto F, et al. Assessing the role of phosphorylated S6 ribosomal protein in the pathological diagnosis of pulmonary antibody-mediated rejection. J Heart Lung Transplant. 2023.

34.

Keller M, Agbor-Enoh S. Cell-free DNA in lung transplantation: research tool or clinical workhorse? Curr Opin Organ Transplant. 2022;27(3):177–83.PubMedPubMedCentralCrossRef

35.

• Khush KK, De Vlaminck I, Luikart H, et al. Donor-derived, cell-free DNA levels by next-generation targeted sequencing are elevated in allograft rejection after lung transplantation. ERJ Open Res. 2021;7(1). This study reviews the importance of cell-free DNA as a non-invasive marker that is detectable by assay, and may predict the onset of graft dysfunction due to AMR.

36.

Agbor-Enoh S, Jackson AM, Tunc I, Berry GJ, Cochrane A, Grimm D, et al. Late manifestation of alloantibody-associated injury and clinical pulmonary antibody-mediated rejection: evidence from cell-free DNA analysis. J Heart Lung Transplant. 2018;37:925–32.PubMedCrossRef

37.

Jang MK, Tunc I, Berry GJ, et al. Donor-derived cell-free DNA accurately detects acute rejection in lung transplant patients, a multicenter cohort study. J Heart Lung Transplant. 2021;40(8):82283. https://doi.org/10.1016/j.healun.2021.04.009.CrossRef

38.

Levine DJ, Glanville AR, Aboyoun C, et al. Antibody-mediated rejection of the lung: a consensus report of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2016;35:397–406.PubMedCrossRef

39.

Tiriveedhi V, Gautam B, Sarma NJ, et al. Pre-transplant antibodies to Kα1 tubulin and collagen-V in lung transplantation: clinical correlations. J Heart Lung Transpl. 2013;32(8):807–14.CrossRef

40.

Haas M, Sis B, Racusen LC, et al. Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transpl. 2014;14:272–83.CrossRef

41.

Hachem RR, Kamoun M, Budev MM, Askar M, Ahya VN, Lee JC, Levine DJ, Pollack MS, Dhillon GS, Weill D, Schechtman KB, Leard LE, Golden JA, Baxter-Lowe L, Mohanakumar T, Tyan DB, Yusen RD. Human leukocyte antigens antibodies after lung transplantation: Primary results of the HALT study. Am J Transplant. 2018;18(9):2285–94.PubMedPubMedCentralCrossRef

42.

Neuhaus K, Hohlfelder B, Bollinger J, Haug M 3rd, Torbic H. Antibody-mediated rejection management following lung transplantation. Ann Pharmacother. 2022;56(1):60–4.PubMedCrossRef

43.

Coutinho AE, Chapman KE. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol. 2011;335(1):2–13.PubMedPubMedCentralCrossRef

44.

Morrell MR, Patterson GA, Trulock EP, et al. Acute antibody-mediated rejection after lung transplantation. J Heart Lung Transplant. 2009;28:96–100.PubMedCrossRef

45.

Roberts DM, Jiang SH, Chadban SJ. The treatment of acute antibody-mediated rejection in kidney transplant recipients-a systematic review. Transplantation. 2012;94:775–83.PubMedCrossRef

46.

Zhang R. Donor-specific antibodies in kidney transplant recipients. Clin J Am Soc Nephrol. 2018;13(1):182–92.PubMedCrossRef

47.

Jordan SC, Toyoda M, Kahwaji J, et al. Clinical aspects of intravenous immunoglobulin use in solid organ transplant recipients. Am J Transplant. 2011;11:196–202.PubMedCrossRef

48.

Durandy A, Kaveri SV, Kuijpers TW, et al. Intravenous immunoglobulins–understanding properties and mechanisms. Clin Exp Immunol. 2009;158(Suppl 1):2–13.PubMedPubMedCentralCrossRef

49.

Golay J, Semenzato G, Rambaldi A, et al. Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics. MAbs. 2013;5:826–37.PubMedPubMedCentralCrossRef

50.

Emer JJ, Claire W. Rituximab: a review of dermatological applications. J Clin Aesthet Dermatol. 2009;2(5):29–37.PubMedPubMedCentral

51.

Neumann J, Schio S, Tarrasconi H, Bortolotto A, Costa C, Machuca T, Camargo S, Sanchez L, Michelon T, Canabarro R, Sporleder H, Fernandes S, Camargo J, Perin F, Felicetti J. Bortezomib in lung transplantation: a promising start. Clin Transpl. 2009;421–4.

52.

Hayes D Jr, Sweet SC, Benden C, Kopp BT, Goldfarb SB, Visner GA, Mallory GB, Tobias JD, Tumin D. Transplant center volume and outcomes in lung transplantation for cystic fibrosis. Transpl Int. 2017;30(4):371–7.PubMedCrossRef

53.

Baum C, Reichenspurner H, Deuse T. Bortezomib rescue therapy in a patient with recurrent antibody-mediated rejection after lung transplantation. J Heart Lung Transplant. 2013;32(12):1270–1. https://doi.org/10.1016/j.healun.2013.08.017. Epub 2013 Sep 13.CrossRefPubMed

54.

Ensor CR, Yousem SA, Marrari M, Morrell MR, Mangiola M, Pilewski JM, D’Cunha J, Wisniewski SR, Venkataramanan R, Zeevi A, McDyer JF. Proteasome inhibitor Carfilzomib-based therapy for antibody-mediated rejection of the pulmonary allograft: use and short-term findings. Am J Transplant. 2017;17(5):1380–8.PubMedCrossRef

55.

Pham C, Pierce BJ, Nguyen DT, Graviss EA, Huang HJ. Assessment of Carfilzomib treatment response in lung transplant recipients with antibody-mediated rejection. Transplant Direct. 2021;7(4):e680.PubMedPubMedCentralCrossRef

56.

Kubiczkova L, Pour L, Sedlarikova L, Hajek R, Sevcikova S. Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma. J Cell Mol Med. 2014;18(6):947–61.PubMedPubMedCentralCrossRef

57.

Dawson KL, Parulekar A, Seethamraju H. Treatment of hyperacute antibody-mediated lung allograft rejection with eculizumab. J Heart Lung Transplant. 2012;31:1325–6. https://doi.org/10.1016/j.healun.2012.09.016.CrossRefPubMed

58.

Muller YD, Aubert JD, Vionnet J, et al. Acute antibody-mediated rejection 1 week after lung transplantation successfully treated with eculizumab, intravenous immunoglobulins, and Rituximab. Transplantation. 2018;102:e301–3.PubMedCrossRef

59.

Kotecha S, Paul E, Ivulich S, Fuller J, Paraskeva M, Levvey B, Snell G, Westall G. Outcomes following ATG therapy for chronic lung allograft dysfunction. Transplant Direct. 2021;7(4):e681.PubMedPubMedCentralCrossRef

60.

Benazzo A, Auner S, Boehm PM, Morscher A, Schwarz S, Vidmar B, Dzubur F, Schweiger T, Hoda AM, Moser B, Matilla JR, Muraközy G, Lang G, Taghavi S, Klepetko W, Hoetzenecker K, Jaksch P. Outcomes with alemtuzumab induction therapy in lung transplantation: a comprehensive large-scale single-center analysis. Transpl Int. 2021;34(12):2633–43.PubMedCrossRef

61.

Benazzo A, Worel N, Schwarz S, Just U, Nechay A, Lambers C, Böhmig G, Fischer G, Koren D, Muraközy G, Knobler R, Klepetko W, Hoetzenecker K, Jaksch P. Outcome of extracorporeal photopheresis as an add-on therapy for antibody-mediated rejection in lung transplant recipients. Transfus Med Hemother. 2020;47(3):205–13.PubMedPubMedCentralCrossRef

62.

Vazirani J, Snell GI, Westall GP. Prolonged survival after lung transplantation in the absence of conventional immunosuppression. J Heart Lung Transplant. 2020;39(10):1159–62. https://doi.org/10.1016/j.healun.2020.06.018. Epub 2020 Jun 27.CrossRefPubMed

63.

Zaffiri L, Hallak R, Leonard S, Neely M, Hulber A, Berry H, Young KA, Reynolds JM. Impact of Belatacept on clinical outcomes in lung transplant patients with antibody-mediated rejection. Am J Transplant. 2022;22(suppl 3)

64.

Spica D, Junker T, Dickenmann M, Schaub S, Steiger J, Rüfli T, Halter J, Hopfer H, Holbro A, Hirt-Minkowski P. Daratumumab for treatment of antibody-mediated rejection after ABO-incompatible kidney transplantation. Case Rep Nephrol Dial. 2019;9(3):149–57.PubMedPubMedCentralCrossRef

65.

January SE, Fester KA, Halverson LP, Witt CA, Byers DE, Vazquez-Guillamet R, Alexander-Brett J, Tague LK, Kreisel D, Gelman A, Puri V, Bahena RN, Takahashi T, Hachem RR, Kulkarni HS. Tocilizumab for antibody-mediated rejection treatment in lung transplantation. J Heart Lung Transplant. 2023;42(10):1353–7.PubMedCrossRef

66.

Jordan SC, Ammerman N, Choi J, Huang E, Najjar R, Peng A, Sethi S, Sandhu R, Atienza J, Toyoda M, Ge S, Lim K, Gillespie M, Zhang X, Haas M, Vo A. Evaluation of Clazakizumab (Anti-Interleukin-6) in patients with treatment-resistant chronic active antibody-mediated rejection of kidney allografts. Kidney Int Rep. 2022;7(4):720–31.PubMedPubMedCentralCrossRef

67.

Kuter DJ, Rogers KA, Boxer MA, Choi M, Agajanian R, Arnold DM, Broome CM, Field JJ, Murakhovskaya I, Numerof R, Tong S. Fostamatinib for the treatment of warm antibody autoimmune hemolytic anemia: Phase 2, multicenter, open-label study. Am J Hematol. 2022;97(6):691–9.PubMedPubMedCentralCrossRef

68.

Mayer KA, Budde K, Halloran PF, Doberer K, Rostaing L, Eskandary F, Christamentl A, Wahrmann M, Regele H, Schranz S, Ely S, Firbas C, Schörgenhofer C, Kainz A, Loupy A, Härtle S, Boxhammer R, Jilma B, Böhmig GA. Safety, tolerability, and efficacy of monoclonal CD38 antibody felzartamab in late antibody-mediated renal allograft rejection: study protocol for a phase 2 trial. Trials. 2022;23(1):270.PubMedPubMedCentralCrossRef

69.

Huang E, Maldonado AQ, Kjellman C, Jordan SC. Imlifidase for the treatment of anti-HLA antibody-mediated processes in kidney transplantation. Am J Transplant. 2022;22(3):691–7.PubMedCrossRef

Title: Antibody-Mediated Rejection: Mechanisms, Pathology, and Therapeutics
Authors: Shourjo Chakravorty
Shambhu Aryal
Adam Cochrane
Steven D. Nathan
Publication date: 30-04-2024
Publisher: Springer US
Keyword: Pathology
Published in: Current Pulmonology Reports
Electronic ISSN: 2199-2428
DOI: https://doi.org/10.1007/s13665-024-00349-w

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com